103 related articles for article (PubMed ID: 33599737)
1. A proactive medical necessity review program reduces revenue loss associated with outpatient medical benefit drugs.
Hawes EM; Misita CP; Amerine LB; Francart SJ
Am J Health Syst Pharm; 2021 Aug; 78(17):1591-1599. PubMed ID: 33599737
[TBL] [Abstract][Full Text] [Related]
2. Prior authorization as a utilization management tool for elective superficial venous procedures results in high administrative cost and low efficacy in reducing utilization.
Lee V; Berland T; Jacobowitz G; Rockman C; Sadek M; Barfield M; Cayne N; Maldonado TS
J Vasc Surg Venous Lymphat Disord; 2020 May; 8(3):383-389.e1. PubMed ID: 31859243
[TBL] [Abstract][Full Text] [Related]
3. Inhouse authorization center to improve reimbursement for outpatient chemotherapy infusions.
Desai SS
Am J Health Syst Pharm; 2011 May; 68(9):828-34. PubMed ID: 21515867
[TBL] [Abstract][Full Text] [Related]
4. Optimizing pharmaceutical reimbursement: one institution's approach.
Loyd LM
Am J Health Syst Pharm; 2006 Nov; 63(21 Suppl 7):S18-21. PubMed ID: 17057056
[TBL] [Abstract][Full Text] [Related]
5. Exploring Cost Savings with Specialty Biologic Drugs Administered to Adult Inpatients with Inflammatory Bowel Disease.
Pitman S; Jones C; Polyak S; Taylor A; Cerven-Jenn D; Reist D
Hosp Pharm; 2022 Feb; 57(1):112-116. PubMed ID: 35521007
[No Abstract] [Full Text] [Related]
6. Reducing Inpatient Psychiatric Unit Denials: A Case Management Quality Improvement Project.
Baum G; Sullivan M; Kohne L; Seaberry C; Powers T
Prof Case Manag; 2022 Nov-Dec 01; 27(6):288-294. PubMed ID: 36206122
[TBL] [Abstract][Full Text] [Related]
7. Contracting to improve your revenue cycle performance.
Welter TL; Semko GA; Miller T; Lauer R
Healthc Financ Manage; 2007 Sep; 61(9):88-95. PubMed ID: 17937124
[TBL] [Abstract][Full Text] [Related]
8. Implementation of a comprehensive medication prior-authorization service.
Leinss R; Karpinski T; Patel B
Am J Health Syst Pharm; 2015 Jan; 72(2):159-63. PubMed ID: 25550140
[TBL] [Abstract][Full Text] [Related]
9. The fall and rise of cost sharing in Kenya: the impact of phased implementation.
Collins D; Quick JD; Musau SN; Kraushaar K; Hussein IM
Health Policy Plan; 1996 Mar; 11(1):52-63. PubMed ID: 10155878
[TBL] [Abstract][Full Text] [Related]
10. Avoidable Technical and Clinical Denial Write-Off Management in Hospitals, Physician Offices, and Clinics.
Terra SM; Byrne A
Prof Case Manag; 2016; 21(2):73-81; quiz E3-4. PubMed ID: 26844714
[TBL] [Abstract][Full Text] [Related]
11. Effective claims denial management enhances revenue.
Hodges J
Healthc Financ Manage; 2002 Aug; 56(8):40-50. PubMed ID: 12222011
[TBL] [Abstract][Full Text] [Related]
12. Optimizing revenue by reducing medical necessity claims denials.
Carter D
Healthc Financ Manage; 2002 Oct; 56(10):88-94, 96. PubMed ID: 12373961
[TBL] [Abstract][Full Text] [Related]
13. Preauthorization Inconsistencies Prevail in Reduction Mammaplasty.
Boyd CJ; Hemal K; Cohen JM; Daar DA; Gwin J; Zupko K; Karp NS
Plast Reconstr Surg Glob Open; 2023 Oct; 11(10):e5361. PubMed ID: 37900990
[TBL] [Abstract][Full Text] [Related]
14. Denials, Dilly-dallying, and Despair: Navigating the Insurance Labyrinth to Obtain Medically Necessary Medications for Pediatric Inflammatory Bowel Disease Patients.
Kahn SA; Bousvaros A
J Pediatr Gastroenterol Nutr; 2022 Oct; 75(4):418-422. PubMed ID: 35836325
[TBL] [Abstract][Full Text] [Related]
15. Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers.
Doshi JA; Puckett JT; Parmacek MS; Rader DJ
Circ Cardiovasc Qual Outcomes; 2018 Jan; 11(1):e003939. PubMed ID: 29326146
[TBL] [Abstract][Full Text] [Related]
16. Multi-Institutional Analysis of Insurance Denial Patterns Within Rhinology.
Janz TA; Khan NS; Dhanda AK; Takashima M; Wu AW; Tang DM; Higgins TS; Ramanathan M; Ahmed OG
Am J Rhinol Allergy; 2024 Jul; 38(4):218-222. PubMed ID: 38544439
[TBL] [Abstract][Full Text] [Related]
17. Establishing a pharmacy revenue integrity team: A blueprint for increasing pharmacy's role in health-system revenue cycle.
Rodgers JKL; Francart SJ; Amerine LB
Am J Health Syst Pharm; 2023 Jul; 80(14):931-938. PubMed ID: 37009909
[TBL] [Abstract][Full Text] [Related]
18. Revenue-cycle redesign: honing the details.
LaForge RW; Tureaud JS
Healthc Financ Manage; 2003 Jan; 57(1):64-71. PubMed ID: 12553235
[TBL] [Abstract][Full Text] [Related]
19. Reducing lost revenue from inpatient medical-necessity denials.
Olaniyan O
Healthc Financ Manage; 2015 Feb; 69(2):74-9. PubMed ID: 26665543
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
